Clinical Trials

Study Title:
A Multi center, Open label, Single arm Phase I Dose escalation and Phase II Dose expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti tumor Activity of FCN 159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

For more information about the trial above please contact the study team:

Principal Investigator, Scott Lindhorst, at lindhors@musc.edu.

Study Coordinator, Jennifer Kinsey, at kinsejen@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina